Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379338860> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4379338860 endingPage "8038" @default.
- W4379338860 startingPage "8038" @default.
- W4379338860 abstract "8038 Background: F182112 is a BCMA x CD3 bispecific antibody that redirects CD3+ T cells to mediate T-cell activation and subsequent lysis of BCMA-expressing myeloma cells.NTP-F182112-001 is a First-in-human, Open-label, Multiple center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients with Relapsed or Refractory Multiple Myeloma. Clinical trial information: NCT04984434. Methods: Eligible patients aged ≥ 18 years had received at least 2 prior multiple myeloma treatment regimens (not including autologous stem cell transplant) including a proteasome inhibitor, an immunomodulatory agent. Three dose cohorts (0.01, 0.1, and 0.3μg/kg) were planned for accelerated titration phase and the following dose cohorts (3, 10,20, and 30 μg/kg) were planed for the i3+3 dose escalation phase. F182112 were administered as QW or Q2W IV infusion. The primary endpoint was safety and tolerability assessed throughout the study by monitoring AEs per the CTCAE 5.0, except CRS per ASTCT 2018. Results: As of Feb 2,2023, 16 pts in the first 7 cohorts received F182112 (0.01-20 μg/kg). Median follow-up was 3.1 mo (range 0.9–11.7; median age 64 y [range 52–74]; 68% female). 9 (56%) pts had received ≥4 prior lines of therapy and 12 (75%) pts were refractory to last lines of therapy. The ORR was 43.8% (95% CI 19.8-70.1) among all enrolled patients (7/16). Of the 9 pts treated with ≥ 10 μg/kg F182112, 6 pts achieved a partial response (PR) or better (overall response rate; 66.7%), including 2 (22.2%) with a very good partial response or better.The most common treatment-related AEs were CRS (81%), lymphopenia (75%; grade 3/4: 69%), neutropenia (63%; grade 3/4: 44%), leukopenia (56%; grade 3/4: 50%), and anemia (31%). CRS and anemia events were all grade 1–2 and median duration time to CRS was 2 days (1-5). One dose-limiting toxicities (transient ALT elevation, grade 3) occurred at the dose group of 10 μg/kg. No pts required a F182112 dose reduction due to AEs. Conclusions: F182112 provides a novel immunotherapy approach for the treatment of Relapsed/ Refractory Multiple Myeloma that may yield improved clinical efficacy in heavily pretreated pts. Clinical trial information: NCT04984434." @default.
- W4379338860 created "2023-06-05" @default.
- W4379338860 creator A5003552301 @default.
- W4379338860 creator A5004271284 @default.
- W4379338860 creator A5006292484 @default.
- W4379338860 creator A5022526821 @default.
- W4379338860 creator A5026662805 @default.
- W4379338860 creator A5044433615 @default.
- W4379338860 creator A5048778510 @default.
- W4379338860 creator A5056321641 @default.
- W4379338860 date "2023-06-01" @default.
- W4379338860 modified "2023-09-26" @default.
- W4379338860 title "Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma." @default.
- W4379338860 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.8038" @default.
- W4379338860 hasPublicationYear "2023" @default.
- W4379338860 type Work @default.
- W4379338860 citedByCount "2" @default.
- W4379338860 countsByYear W43793388602023 @default.
- W4379338860 crossrefType "journal-article" @default.
- W4379338860 hasAuthorship W4379338860A5003552301 @default.
- W4379338860 hasAuthorship W4379338860A5004271284 @default.
- W4379338860 hasAuthorship W4379338860A5006292484 @default.
- W4379338860 hasAuthorship W4379338860A5022526821 @default.
- W4379338860 hasAuthorship W4379338860A5026662805 @default.
- W4379338860 hasAuthorship W4379338860A5044433615 @default.
- W4379338860 hasAuthorship W4379338860A5048778510 @default.
- W4379338860 hasAuthorship W4379338860A5056321641 @default.
- W4379338860 hasConcept C121332964 @default.
- W4379338860 hasConcept C126322002 @default.
- W4379338860 hasConcept C141071460 @default.
- W4379338860 hasConcept C142424586 @default.
- W4379338860 hasConcept C143998085 @default.
- W4379338860 hasConcept C159654299 @default.
- W4379338860 hasConcept C197934379 @default.
- W4379338860 hasConcept C203014093 @default.
- W4379338860 hasConcept C203092338 @default.
- W4379338860 hasConcept C2776364478 @default.
- W4379338860 hasConcept C2778375690 @default.
- W4379338860 hasConcept C2780868878 @default.
- W4379338860 hasConcept C31760486 @default.
- W4379338860 hasConcept C535046627 @default.
- W4379338860 hasConcept C71924100 @default.
- W4379338860 hasConcept C87355193 @default.
- W4379338860 hasConcept C90924648 @default.
- W4379338860 hasConceptScore W4379338860C121332964 @default.
- W4379338860 hasConceptScore W4379338860C126322002 @default.
- W4379338860 hasConceptScore W4379338860C141071460 @default.
- W4379338860 hasConceptScore W4379338860C142424586 @default.
- W4379338860 hasConceptScore W4379338860C143998085 @default.
- W4379338860 hasConceptScore W4379338860C159654299 @default.
- W4379338860 hasConceptScore W4379338860C197934379 @default.
- W4379338860 hasConceptScore W4379338860C203014093 @default.
- W4379338860 hasConceptScore W4379338860C203092338 @default.
- W4379338860 hasConceptScore W4379338860C2776364478 @default.
- W4379338860 hasConceptScore W4379338860C2778375690 @default.
- W4379338860 hasConceptScore W4379338860C2780868878 @default.
- W4379338860 hasConceptScore W4379338860C31760486 @default.
- W4379338860 hasConceptScore W4379338860C535046627 @default.
- W4379338860 hasConceptScore W4379338860C71924100 @default.
- W4379338860 hasConceptScore W4379338860C87355193 @default.
- W4379338860 hasConceptScore W4379338860C90924648 @default.
- W4379338860 hasIssue "16_suppl" @default.
- W4379338860 hasLocation W43793388601 @default.
- W4379338860 hasOpenAccess W4379338860 @default.
- W4379338860 hasPrimaryLocation W43793388601 @default.
- W4379338860 hasRelatedWork W1968036257 @default.
- W4379338860 hasRelatedWork W2053485995 @default.
- W4379338860 hasRelatedWork W2107697672 @default.
- W4379338860 hasRelatedWork W2109512293 @default.
- W4379338860 hasRelatedWork W2378369323 @default.
- W4379338860 hasRelatedWork W3212096909 @default.
- W4379338860 hasRelatedWork W4205626317 @default.
- W4379338860 hasRelatedWork W4304479650 @default.
- W4379338860 hasRelatedWork W4310217075 @default.
- W4379338860 hasRelatedWork W4384922324 @default.
- W4379338860 hasVolume "41" @default.
- W4379338860 isParatext "false" @default.
- W4379338860 isRetracted "false" @default.
- W4379338860 workType "article" @default.